Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Sparlon For ADHD To Get Psychopharm Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

The March 23 review of the new indication for modafinil, currently marketed as Provigil for narcolepsy, will likely focus on safety differences compared to other ADHD drugs.

You may also be interested in...



Sparlon Shows 31 Cases Of Suicidality, Aggression or Psychosis In ADHD Database

Incidence of events with Sparlon is higher than for placebo but exposure in patients is also greater, FDA summary of clinical adverse events states.

Sparlon Shows 31 Cases Of Suicidality, Aggression or Psychosis In ADHD Database

Incidence of events with Sparlon is higher than for placebo but exposure in patients is also greater, FDA summary of clinical adverse events states.

Cephalon Looks To Q2 For Launch Of Sparlon

Cephalon has pushed back the anticipated launch of its attention deficit/ hyperactivity disorder drug Sparlon (modafinil) from Q1 until the second quarter, pending the outcome of a review by FDA's Psychopharmacologic Drugs Advisory Committee March 23

Related Content

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel